University of Connecticut
Masthead Logo
Master's Theses

OpenCommons@UConn
University of Connecticut Graduate School

5-12-2019

The Effectiveness of Medication Assisted
Treatment (MAT) Programs in Correctional
Facilities: A Review of the Evidence and
Recommendations
Woodlyn Joachim
woodlyn.joachim@uconn.edu

Recommended Citation
Joachim, Woodlyn, "The Effectiveness of Medication Assisted Treatment (MAT) Programs in Correctional Facilities: A Review of the
Evidence and Recommendations" (2019). Master's Theses. 1364.
https://opencommons.uconn.edu/gs_theses/1364

This work is brought to you for free and open access by the University of Connecticut Graduate School at OpenCommons@UConn. It has been
accepted for inclusion in Master's Theses by an authorized administrator of OpenCommons@UConn. For more information, please contact
opencommons@uconn.edu.

The Effectiveness of Medication Assisted Treatment (MAT) Programs in Correctional
Facilities: A Review of the Evidence and Recommendations

Woodlyn Joachim

B.S, University of Connecticut, 2018

A Thesis
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Master of Public Health
At the
University of Connecticut
2019

ii

Copyright by
Woodlyn Joachim

2019

iii

APPROVAL PAGE
Master of Science Thesis
The Effectiveness of Medication Assisted Treatment (MAT) Programs in Correctional
Facilities: A Review of the Evidence and Recommendations

Presented by
Woodlyn Joachim, B.S.

Major Advisor
________________________________________________________________
Richard Stevens, PhD

Major Advisor
________________________________________________________________
Zhao Helen Wu, PhD

Associate Advisor
_____________________________________________________________
Marwan Haddad, MD, MPH

University of Connecticut
2019

iv

Acknowledgments

To my mother, Rose Phenia Nerelus, thank you for inspiring me to aim for the best in
life. I owe much of my success today to you. Thank you for the valuable lessons that you have
taught me over the years, the encouragement, the prayers, and most importantly, the sacrifices
that you have made in order to see me become the woman that I am today. Mèsi manman.
To my advisors, Dr. Richard Stevens, Dr. Helen Wu (Zhao), and Dr. Marwan Haddad
thank you for your guidance during this journey. I enjoyed learning from all of you. The
lessons and skills that you have taught me both in the classroom and while working on this
project were priceless. Thanks to your support, I am confident that I will make an impact in
this world as an advocate for public health and, one day, as a member of a teaching faculty.
The MPH faculty and staff, especially Dr. David Gregorio and Ms. Barbara Case, you
have made my experience in the MPH program so rewarding! Dr. Gregorio, mèsi anpil pou
tout sakrifis ou fè pou elèv ou yo. Ms. Case, thank you for always looking out for us and
sending us your kind reminders!
To my partner, Keron Johnson, you have been an amazing support system for me.
Every person needs to have someone in their life that they can count on. I am glad to have you
as this individual in mine. Thank you for your constant love and emotional support. Your
support has meant more to me than you could imagine. You are one of the best proofreaders I
know! Je t’aime.
Lastly, my sincere thanks also go to my friends and co-workers Janet Oputa, Lauren
Bifulco, Sarafina Robinson, and Dr. LaKisha Grant-Washington, for offering me the
opportunity to work under their guidance while pursuing my masters. I will forever cherish
the lessons that I have learned while working with all of you.
I dedicate this thesis to my mother, Rose Phenia Nerelus.

v

Table of Contents

The Effectiveness of Medication Assisted Treatment (MAT) Programs in Correctional Facilities: A
Review of the Evidence and Recommendations .....................................................................................................I
APPROVAL PAGE ............................................................................................................................................................. III
Acknowledgements.......................................................................................................................................................... IV
Table of Contents ............................................................................................................................................................... V
Prevalence of Opioid Use Disorders (OUDs) in the United States ................................................................. 1
The Post-Release Consequences of Improper Treatment for OUD during Incarceration .............. 2
Benefits of Providing Buprenorphine for MAT in Correctional Settings ............................................... 6
Methods ................................................................................................................................................................................. 7
Results ................................................................................................................................................................................. 10
Discussion ........................................................................................................................................................................... 16
Gaps in Literature and Limitations...................................................................................................................... 17
Ethical Consideration for MAT in Correctional facilities and Future Recommendations............. 17
The Evidence is there, Now What? ...................................................................................................................... 18
Treatment Readiness and Social Support......................................................................................................... 19
Cost of Treatment: Methadone vs. Buprenorphine ...................................................................................... 20
Financial Resources ................................................................................................................................................... 21
Access to Care Post-release .................................................................................................................................... 22
Implementing Statewide Interventions in Correctional Facilities ......................................................... 24
Conclusion .......................................................................................................................................................................... 24
References .......................................................................................................................................................................... 26
Appendix A ......................................................................................................................................................................... 38
Appendix B ......................................................................................................................................................................... 41

A Review of the Effectiveness of MAT Programs in Correctional Settings

1

The Effectiveness of Medication Assisted Treatment (MAT) Programs in Correctional
Facilities: Review of the Evidence and Recommendations

Prevalence of Opioid Use Disorders (OUDs) in the United States
Since its emergence in the 1990s, the opioid epidemic continues to affect millions of
Americans each year (Paulozzi, Budnitz, & Xi, 2006). In 2015, more than 20.5 million
Americans were diagnosed with opioid use disorders (OUDs), 2 million of whom abused
prescription pain relievers (L. Gowing, Farrell, Bornemann, Sullivan, & Ali, 2008). Every
year, heroin, synthetic opioids, and prescription opioids account for most opioid overdoserelated deaths, with prescription painkillers accounting for more than half of these incidents
(Paulozzi, Budnitz, & Xi, 2006). Additionally, with more than 52,404 lethal drug overdoses in
2015, a drug-related overdose is now the leading cause of accidental death in the United
States (Rudd et al., 2016). Between 2014 and 2015, the death rate from synthetic opioids other
than methadone significantly increased by 72.2% (Rudd et al., 2016). Specifically, heroinrelated overdose rates saw the second highest increase of 20.6% across all demographic
groups, regions, and states (Rudd et al., 2016). Natural and semisynthetic opioid-related death
rates increased by 2.6% while methadone death rates decreased by 9.1% (Rudd et al., 2016).
The prevalence of Opioid use disorder is particularly devastating in US prisons. While
only 5% of the general population meet the criteria for substance use disorders, as many as
58% of state prisoners and 63% of sentenced jail inmates meet the criteria for drug
dependence (Bronson et al., 2017). Among the 2.3 million people incarcerated in the U.S,
more than 200,000 of them have opioid dependence (State & Population, 2018). This
translates that approximately 24 to 36% of all individuals with Opioid Use Disorders (OUDs)
involving heroin go to prison in the United States (Boutwell, Nijhawan, Zaller, & Rich, 2007).
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Despite the high demand for opioid-substitution treatment in correctional settings, access to
proper treatment in jail and prisons remains scarce (Bronson et al., 2017). The lack of proper
treatment during incarceration is associated with negative health outcomes post-release
(Bronson et al., 2017). In fact, during their transitions to their communities, former inmates
are at higher risks of relapse, drug overdose, and more.

The Post-Release Consequences of Improper Treatment for OUD during Incarceration
Relapse: Without proper substance use treatment, formerly incarcerated individuals
face high rates of relapse to alcohol and illicit drugs post-release (Dolan et al., 2005; Dole et
al., 1969; Farrell & Marsden, 2008; Favrod-Coune et al., 2013). In fact, during the first year
after release, 85-90% of former inmates relapse to opioid use (Gordon et al., 2014). Merrall
and colleagues (2010) suggested that formerly incarcerated individuals may experience high
relapse rates post-release due to social isolation and loss of tolerance during prison. This
highlights the importance of providing proper treatment to those with OUD during
incarceration. Despite the high rate of relapse to heroin and other illicit drugs, inmates have
limited to no access to proper treatment during incarceration (Bronson et al., 2017; Gordon et
al., 2014; Merrall et al., 2010). Similarly, many of them remain untreated upon release (Dolan
et al., 2007; Gordon et al., 2014; Stöver, Kastelic, & Pont, 2008).
Overdose: Individuals with OUDs who have been incarcerated also have the highest
risk of a fatal opioid-related overdose of any subpopulation during community re-entry
(Binswanger et al., 2007; Boutwell et al., 2007). A study assessing the risk of death among
inmates soon after their release found that their adjusted risk for overdose-related death was
3.5 times that among state residents (Binswanger et al., 2007). Specifically, overdose-related
incidents risks were 12-fold higher than would be expected in similar demographic groups
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(Binswanger et al., 2012). With an adjusted relative risk of 129, overdose risk was the highest
during the first few weeks after release (Binswanger et al., 2012). During the first two weeks,
their adjusted risk of death was 12.7 times higher than other state residents (Binswanger et al.,
2007).
In another study investigating all causes of mortality for formerly incarcerated
individuals in Washington between 1999 and 2009, overdose was the leading cause of death
(Binswanger, Blatchford, Mueller, & Stern, 2013). Overdose deaths in former prisoners
accounted for approximately 8.3% of the overdose deaths recorded among individuals aged 15
to 84 years in the state of Washington between 2000 and 2009 (Binswanger et al., 2013).
Infectious Disease Risk Behaviors. Communities with the highest rate of heroin users
simultaneously experience high rates of Hepatitis C (HCV) diagnoses (“Centers for Disease
Control and Prevention, 2013). The rate of new HCV infection increased by 150% from 2010
to 2013 in communities with young drug users (“Centers for Disease Control and Prevention”,
2013; Zibbell et al., 2015). Similarly, HCV prevalence ranges between 30-40% among
prisoners in the United States (Center for Disease Control and Prevention, 2003). In prisons,
the rate of HIV and AIDS among those with substance use disorders is 3 to 4 times greater
than the rates found in the general population. Similarly, relapse to opioid and other illicit
drugs post-release is associated with high rates of mortality and poor HCV and HIV treatment
outcomes (Curcio, Franco, Topa, & Baldassarre, 2011; Dole et al., 1969; Farrell & Marsden,
2008; Favrod-Coune et al., 2013; Fazel, Bains, & Doll, 2006; Friedmann et al., 2012;
Spaulding et al., 2009).Yet, fewer than 33% of individuals who use drugs receive proper
substance use, HCV, and HIV care (Zibbell et al., 2015).
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Methadone and Buprenorphine for Medication Assisted Treatment (MAT)
Many drugs have been extensively used and studied for the treatment of OUDs in
criminal justice settings (Nunn et al., 2009). Medications used to treat opioid dependence
include methadone and buprenorphine, with methadone maintenance therapy (MMT) being
used by the majority of correctional facilities that offer Medication-assisted treatment for
OUD (Marshall et al., 2017; Nunn et al., 2009).
Methadone. Methadone is a full mu opioid agonist used to treat heroin and other
opioid dependence (Marshall et al., 2017). According to Marshall and colleagues (2017),
methadone is an effective maintenance therapy option and a detoxification agent due to its
slow onset of action and extended half-life ranging from 24 to 36 hours. Additionally,
methadone treatment has been associated with positive health outcomes, including increased
treatment retention and reduction in IV drug use, criminal activity, HIV risk behaviors, and
drug overdose-related mortality (Dole et al., 1969; L. R. Gowing, Farrell, Bornemann,
Sullivan, & Ali, 2006; Gronbladh, Ohlund, & Gunne, 1990; Newman & Whitehill, 1979).
Nevertheless, a national report in 2007 showed that MMT was available to less than 20% of
Americans with opioid dependence (Cunningham, Kunins, Roose, Elam, & Sohler, 2007).
Since the 1970s, many countries, including Canada, France, the Netherlands,
Australia, and Spain, started implementing the use of methadone-maintenance therapy (MMT)
for the treatment of OUD in corrections facilities (Dolan et al., 2003; Haig, 2003; Hall, Ward,
& Mattick, 1993; Langendam et al., 1998; Perez de los Cobos et al., 2004). To date, the
United States has more than 3200 county jails and 1800 state and federal prisons (Lee et al.,
2015; Vestal, 2016). Unfortunately, in 2008, less than 0.1% of incarcerated individuals with
OUD received any form of medication-assisted treatment (Larney & Dolan, 2009).
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Many corrections agencies prefer the use of non-medicated approaches, such as
counseling for forced withdrawal, to treat opioid use disorder among incarcerated individuals
(Brinkley-Rubinstein et al., 2018). This is mostly due to the lack of resources in these
facilities, security concerns regarding proper medication dispersion, stigma associated with
MMT, and the lack of knowledge about the effectiveness of methadone for medicationassisted treatment (Brinkley-Rubinstein et al., 2018; Gordon et al., 2014; Nunn et al., 2009).
However, MMT has been shown to be an effective, evidence-based approach to address
opioid use disorder in the prison population and improve post-release health outcomes of
inmates (Connock et al., 2007; Degenhardt & Hall, 2012; Kinlock, Gordon, Schwartz,
Fitzgerald, & O’Grady, 2009; Mattick, Breen, Kimber, & Davoli, 2009; McKenzie et al.,
2012; Rich et al., 2015).
Buprenorphine. Buprenorphine is a synthetic opioid used as an agonist substitution
treatment for pain and opioid dependence (Kumar & Saadabadi, 2019). Buprenorphine for
medication-assisted treatment (MAT) has been extensively studied since the 1970s and is an
effective and safe opiate dependence psychotherapy (Wesson & Ling, 2003). The Drug
Addiction Treatment Act of 2000 (DATA 2000) allowed primary care physicians to become
qualified to prescribe buprenorphine in settings other than an opioid treatment program
(OTP). Nevertheless, demand for treatment continues to outgrow the number of DATAwaived providers allowed and willing to prescribe buprenorphine for MAT (Wesson & Ling,
2003).
Buprenorphine could be an alternative to methadone maintenance treatment for opioid
use disorders during incarceration (Magura et al., 2009; Vocci et al., 2015). Unlike
methadone, the use of buprenorphine for MAT has less associated stigma, fewer regulations in
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the United States, can be administered on alternate days, and has been shown to facilitate
entry in community-based MAT programs (Dasgupta et al., 2010; Lee et al., 2015; Magura et
al., 2009).

Benefits of Providing Buprenorphine for MAT in Correctional Settings
Benefits of Buprenorphine for MAT in Correctional Settings are a multitude. Findings
from an observational study conducted in England suggested that the implementation of
prison-based buprenorphine for opioid substitution therapy may reduce drug-related mortality
rates by 85% in the first month after release (Marsden et al., 2017). Making substance abuse
treatment available to those in need in the criminal justice system could significantly lower
the demands for drugs and reduce the rates of drug overdose-related deaths (Pizzicato, Drake,
Domer-Shank, Johnson, & Viner, 2018).
Additionally, findings from a retrospective study suggest that compared to patients
who do not adhere to buprenorphine treatment, patients retained in buprenorphine treatment
have higher likelihood to gain access to HCV treatment (22.4% vs. 8.5%, p <0.05), initiate
treatment (9.2% vs. 6.4%, p = 0.6), and achieve positive HCV- related health outcomes
(40.8% in the retained group vs. 21.3% not retained, p<0.05) and (Norton et al., 2017). The
use of a multidisciplinary approach that incorporates substance use care, such as medicationassisted treatment, and HCV treatment may lead to better health outcomes in individuals with
substance use disorders who are co-infected with HCV (Bruggmann & Litwin, 2013; Robaeys
et al., 2013; Springer, Qiu, Saber-Tehrani, & Altice, 2012). Similarly, international guidelines
support the integration of methadone for medication-assisted treatment with HIV- treatment
(Martin & Wang, 2013). Despite the evidence of the efficacy of integrating the use of opioid
therapy treatment with HIV and HCV care to achieve maximal viral suppression in prisoners
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infected with HIV, few correctional facilities have implemented the use of integrated HIV or
HCV treatment and MAT (Springer et al., 2012).
Medication-assisted treatment (MAT) can help improve the health outcomes of
individuals with OUD during their transition period after release (Magura et al., 2009; Norton
et al., 2017). Yet, access to MAT remains scarce in jails and prisons (Bronson et al., 2017). In
fact, only 28% of prisoners and 22% of jail inmates who met the criteria for severe substance
use disorders received proper medical treatment (Bronson et al., 2017). The objective of this
study is to provide a narrative review of evidence on the long-term, post-release outcomes of
implementing pre-release buprenorphine or methadone for MAT in correctional settings.
Specifically, we will evaluate the effectiveness of the initiation of buprenorphine and
methadone for MAT during incarceration in 1) increasing the likelihood of treatment
continuation after release and 2) reducing the rate of relapse and overdose deaths during the
transitioning period.

Methods
This study aims to answer the following question: “How can the implementation of
medication-assisted treatment (MAT) programs in correctional settings improve the postrelease health outcomes of individuals with opioid use disorders?” We hypothesize that the
implementation of MAT in criminal justice settings can improve the health outcomes of
individuals by increasing their likelihood of treatment continuation and decreasing their risk
of relapse and drug-related overdose death upon release.
Search Strategy
We searched PubMed and PsycINFO to identify studies published between 2009 and
2019 that evaluated the effectiveness of MAT in jails and prisons in the United States. To be
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included in this analysis, studies must have a comparison group. Animal studies, crosssectional studies, incomplete studies (pilot studies, preliminary reports), studies conducted in
inpatient hospitals or residential rehabilitation facilities, and studies published prior to January
1, 2009, were excluded from this analysis.
Our search strategy included terms related to medical subject headings, correctional
facilities, and MAT programs in various combinations. Additionally, we searched through
reference lists of relevant articles for additional studies that were not included in our results
when employed the first search strategy. Upon the removal of duplicated studies, the author
independently reviewed titles and abstracts, followed by full-text screening, to identify
relevant studies. Mendeley was used to organize publication records, identify duplicates, and
find citations.
Comparators
This study includes 4 types of comparison studies: (1) studies comparing patients who
received pre-release MAT treatment and those who received other types of intervention, (2)
studies comparing patients who received pre-release MAT services and those who received
treatment post-release, and (3) studies comparing different medications used for MAT (i.e.
buprenorphine vs. methadone).
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Initial Screen (PubMed and PsychINFO)
N = 375

Record upon removal of duplicates
N = 72
Excluded publications based on title/
abstract
N = 58
Full text articles reviewed for eligibility
N = 14
Excluded publications upon full text
review
N=6

Included studies
N=8
Figure 1. Literature Flow Diagram
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Results
Eight studies are summarized in table 1. All eight studies were randomized clinical
trials (RCTs). Four were conducted in Rhode Island, two in Baltimore, one in Connecticut,
and one in New York City. Treatment and comparisons were all drawn from incarcerated
individuals with diagnosed opioid use disorders. Interventions involved the use of methadone
maintenance treatment (four) and buprenorphine treatment (four). One study followed up
with participants at one-month post-release; two at three months; four at six months; and three
at twelve months post-release. Table 2 summarizes the evidence on the impact of each
intervention on the post-release health outcomes of study participants. The table provides a
synthesis of the studies per outcome with positive change or no effect. The evidence is
consistent regarding retention in treatment post-release, relapse (drug use) and overdose.
Inconsistent evidence was found regarding infectious disease risk behaviors and other
outcomes, such as re-incarceration, criminal activity, visits to the emergency room, and
hospital admissions.
Methadone
Treatment Continuation
Brinkley-Rubinstein and colleagues (2018) conducted a randomized clinical trial study
in a combined prison and jail facility in Rhode Island to measure the long-term outcomes of
methadone treatment during incarceration compared to forced withdrawal at 12 months postrelease. Although not statistically significant, those who received MMT were more likely to
engage in continuous MMT at 12 months (Brinkley-Rubinstein et al., 2018). Specifically,
43.6% of the methadone group continued MMT treatment compared to 38.8% of the forced
withdrawal group (Brinkley-Rubinstein et al., 2018).
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Another randomized clinical trial study assessed the efficacy of prison-initiated MMT
compared to post-release community MMT or pre-release counseling with a passive referral
for methadone treatment in the community after release (Kinlock et al., 2009). Individuals in
counseling + methadone group reported a higher mean number of days enrolled in a
community-based treatment compared to their counseling + transfer and counseling only
groups (166 vs. 91.3 vs. 23.1 days, respectively). Additionally, the counseling methadone
group individuals were more likely to remain in treatment for one year compared to the other
two groups. Seventy percent of the methadone group remained in treatment for 365 days
compared to 53.6% of the counseling and transfer group, and none of the counseling-only
group (all ps< 0.01).
Similarly, a 3-arm randomized controlled trial study compared the long-term
outcomes of initiating methadone treatment pre-release compared to post-release initiation of
treatment (McKenzie et al., 2012). In this study, arm 1 consisted of individuals who initiated
methadone pre-release and continued methadone treatment post-release with financial
assistance, arm 2- were referred to a methadone program post-release with financial
assistance, and arm 3 were referred to a methadone program, but were not offered financial
assistance. In this study, 80% of arm 1 participants entered treatment within 30 days of release
compared to 41% of arm 2 participants and 22% of arm 3 participants (p< 0.001).
Rich et al., (2015) conducted an open-label trial to compare the post-release outcomes
of methadone during incarceration versus forced withdrawal from methadone. Participants
assigned in the methadone group were more than twice as likely to return to community
methadone clinic within the first-month post-release compared to those in the forced
withdrawal group (97% vs. 77% respectively, p< 0.00001) (Rich et al., 2015). Methadone
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participants were also more likely to attend methadone treatment after release. These
participants were 7 times more likely to get methadone treatment post-release than those who
underwent forced withdrawal from methadone (Rich et al., 2015).
Relapse and Drug-Overdose Related Mortality
Brinkley-Rubinstein and colleagues (2018) also observed a significant difference in
drug use among the methadone group. Individuals who received MMT on the day before
release were significantly less likely to report using heroin (p= 0.0467) and injecting other
illicit drugs (p= 0.0033) in the past 30 days at 12-month follow-up compared to those who
were not dosed with methadone the day before release (Brinkley-Rubinstein et al., 2018).
Additionally, the group dosed with methadone the day before release were less likely to
experience non-fatal overdose (p= 0.0390).
In Kinlock et al., (2009) the group who received counseling + methadone treatment in
prison was significantly less likely to be opioid-positive at 12 months post-release compared
to the counseling plus a transfer to a community methadone program and the counseling-only
groups (p= 0.008). Specifically, 65.6% of counseling only group were opioid-positive at the
12 month follow-up period compared to 48.7% counseling plus transfer group, and 25.0% of
counseling + methadone group (p= 0.002). There were also statistically significant differences
in urine cocaine test results among the 3 groups. Seventy-one percent of the counseling-only
group tested positive for cocaine at 12 months compared to 66.6% counseling+ transfer group,
and 43.2% of the counseling + methadone group (ps < 0.05).
In McKenzie et al., 2012, 14% of methadone pre-release participants (arm 1) relapsed
to heroin use at 6-month follow-up compared to 56% of referred MMT participants with
payment (arm 2) and 44% of MMT referral only participants (arm 3) (p= 0.008). Additionally,
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arm 1 participants were statistically significantly less likely to report cocaine use (19%)
compared to arm 2 (41%) and arm 3 (33%) participants (p= 0.06).
In Rich and colleagues (2015), 8% of the continued methadone group reported opioid
and 64% reported other drug use at 1-month post-release. In the forced withdrawal group,
18% reported opioid use while 76% reported using other drugs (P= 0.033 for opioid use and
0.065 for other drug use) (Rich et al., 2015).
Infectious Diseases Transmission
No studies reported data on the impact of methadone maintenance treatment (MMT) in
correctional settings on HIV or HCV incidence. Rubenstein et al., (2018) found no
statistically significant differences for transactional sex and other HIV risk behaviors among
the 3 study groups. Rich et al., (2015) found that the methadone group was less likely to
report the use of injectable illegal drugs (17% vs. 32%, p= 0.016). Kinlock et al., (2009)
reported one death from AIDS in the counseling + methadone group. It is unclear whether the
individual became infected with AIDS prior to or after incarceration.
Buprenorphine
Treatment Continuation
Magura et al., 2009 found that pre-release initiation of buprenorphine for substance
use treatment is more effective than other treatments when it comes to increasing the
likelihood of treatment continuation after release. In this study, researchers wanted to examine
if the use of buprenorphine can be as effective as methadone for MAT in a jail setting. At
entry, ninety- three percent of buprenorphine patients stated their intention to continue
treatment after release compared to 44% of those in the methadone group (p < 0.001).
Although not statistically significant, participants in the buprenorphine were also more likely
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to complete their treatment in jail compared to those in the methadone group (82% vs. 75%)
(Magura et al., 2009).
Additionally, the buprenorphine group reported to their assigned post-release
treatment in the community after release more often than the methadone group (48% vs. 14%,
p< 0.001) (Magura et al., 2009). The buprenorphine group was also more likely to attend their
medication-assisted treatment sessions than methadone patients (48% vs. 23%, p< 0.005).
Interestingly, five of the 56 methadone patients chose to receive buprenorphine treatment
rather than methadone treatment after release whereas none of the buprenorphine patients
transferred to a methadone provider after release. The authors believe that buprenorphine
treatment may have been more feasible for those individuals who transferred from the
methadone group. Unlike methadone programs, which are highly regulated, buprenorphine
programs can be provided in flexible clinic- and office-based settings, which may increase the
rate of patients’ reporting for treatment (Magura et al., 2009).
Gordon et al., (2017) examined the long-term, post-release outcomes among prisoners
who participated in a randomized clinical trial study to assess the impacts of implementing
buprenorphine treatment pre-release vs. post-release from prison. They found that former
prisoners who initiated buprenorphine treatment in prison had a higher mean number of days
retained in treatment upon release compared to the control group, who received treatment after
release. The pre-release group had a mean number of 65.9 days while the control group only
reported 21.8 days in treatment (p= 0.005) (Gordon et al., 2017).
Zaller and colleagues (2013) found that initiating buprenorphine prior to release
increased linkage to treatment and attendance to treatment appointments post-release. Ninetytwo percent of participants who started buprenorphine treatment in prison were linked to care
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in their community. Eighty-three percent of them remained in treatment for 6 months, and
reported an average of 3.9 days to their first appointment, a mean of 20.3 weeks, and a median
of 24 weeks in treatment (Zaller et al., 2013). Among the control group (initiated
buprenorphine after release), 73% were referred to buprenorphine treatment in the
community. Among them, 78% linked to care in the community and 34% remained in care for
6 months. Those who remained in treatment reported a mean of 9.2 days to their first
appointment and remained in treatment for 13.2 weeks (Zaller et al., 2013). Specifically, at 24
weeks, 91% of participants in the pre-release group remained in treatment while 34% of the
post-release individuals who initiated treatment after release did so (p= 0.005).
Relapse and Drug-Overdose Related Mortality
Zaller et al., (2013) also found that pre-release initiation of buprenorphine decreased
opiate use and overdose-related incidents upon release. None of the participants who initiated
buprenorphine treatment in prison reported the use of opiate, drug injection or an overdose at
the 6 months post-release follow-up period. On the other hand, 23.1% of the post-release
group reported heroin use (p= 0.08), 26.9% reported injecting drugs (p= 0.05), and 11.5%
experienced a non-fatal overdose incident during their 6 months follow-up period (p= 0.23).
Infectious Diseases Transmission
No studies conducted between 2009 and 2019 investigated the effectiveness of
integrating buprenorphine and HIV or HCV treatment to treat OUD and maintain maximal
viral suppression during incarceration and after release from prison. However, a prospective
study evaluated the efficacy of buprenorphine for MAT after release to sustain viral
suppression among former inmates with HIV who were part of a clinical trial (Springer et al.,
2012). Springer et al., (2012) found a positive association between enrollment in a
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buprenorphine treatment program and maximal viral suppression (Springer et al., 2012).
Individuals retained in buprenorphine treatment for 24 weeks were more likely to sustain
maximal viral suppression (MVS) compared to those who received buprenorphine, but failed
to remain in treatment for 24 weeks (OR= 4.32, p= 0.03) (Springer et al., 2012).

Discussion
Both methadone and buprenorphine for medication-assisted treatment during
incarceration are significantly associated with better treatment retention rates after release.
Majority of the studies found better treatment retention outcomes post-release among both
individuals who received buprenorphine or methadone during incarceration (Rubenstein et al.,
2018; Kinlock et al., 2009; Magura et al., 2009; Gordon et al., 2017; Zaller et al., 2013; Rich
et al., 2015). Access to medication-assisted treatment in correctional facilities may also be
associated with reduced risks of drug use (Rubenstein et al., 2017; Kinlock et al., 2009;
McKenzie et al., 2012; Zaller et al., 2013), drug-related overdose (Rubenstein et al., 2017),
recidivism (Zaller et al., 2013), and HIV risk behaviors (Springer et al., 2012; Rich et al.,
2015).
Evidence is lacking regarding the impacts of integrating medication-assisted treatment
and HCV/ HIV care on the post-release incidence and HIV/ HCV-related risk behaviors
among individuals previously incarcerated in the United States. None of the studies
summarized implemented the integration of HIV or HCV care and MAT. However, Rich et
al., (2015) and Springer et al., (2012) both found that retention in treatment post-release was
positively associated with maximal viral suppression and lower risk in HIV- risk behaviors.
Another systematic review suggested that providing medication-assisted treatment in
correctional settings may reduce risk behaviors among individuals with OUD and reduce HIV
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incidence post-release (L. Gowing et al., 2008).

Gaps in Literature and Limitations
Studies included in this analysis had important methodological limitations (refer to
Table 2). Possible sources of bias include selection bias, social desirability bias, and lack of
generalizability of findings. Studies conducted in Rhode Island recruited participants from a
unified prison and jail system (Rubenstein et al., 2017; McKenzie et al., 2012; Zaller et al.,
2013; Rich et al., 2015). This may have affected the generalizability of their findings.
Similarly, most participants included in the summarized studies were males. Additionally,
differential rates of follow-up and the use of self-reported data may have resulted in selection
bias and social desirability bias. Previous studies have found that participants with poor
outcomes are more likely to be lost to follow-up, which may result in overestimation of
treatment benefits (Marco et al., 2013).
This review could not clarify several questions. There was insufficient evidence on the
effectiveness of integrating MAT programs and HIV/ HCV care in correctional settings in
reducing infectious disease risk behaviors and incidence post-release. None of the studies
conducted a needs assessment with prisoners to identify protective and risk factors related to
retention in treatment and other post-release outcomes. Further research is needed to evaluate
the struggles that former inmates face during community re-entry that may affect their ability
to continue treatment and achieve positive health outcomes.

Ethical Consideration for MAT in Correctional facilities and Future Recommendations
With over 2 million incarcerated individuals, the United States has an incarceration
rate of 500 prisoners per 100,000 residents, the highest rate in the world since 2010 (Guerino,
Harrison, Sabol, & Statisticians, 2011). Between 1980 and 2016, the number of individuals
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imprisoned for drug offenses increased from 40,900 to 450,000 (State & Population, 2018).
Despite the overrepresentation of individuals with OUD in correctional facilities, access to
proper opioid substitution treatment, such as methadone or buprenorphine for MAT remains
scarce (Connock et al., 2007; Friedmann et al., 2012; Mintzer et al., 2007).
According to the Court ruling in Estelle v Gamble, neglection of a prisoner’s illness
constitutes cruel and unusual punishment that violated the eighth amendment (Rosenfeld,
2016). Withholding treatment and care to those in need in the criminal justice system is
morally and ethically questionable (Rosenfeld, 2016). Despite this ruling and the agreement
that opioid use disorder is a disease, the quality of care to treat opioid use disorder in
correctional facilities remains limited (Taxman, Perdoni, & Harrison, 2007). Less than 35
percent of courts in the United States permit the implementation of medication-assisted
treatment programs in the prisons and jails (Allen, Wakeman, Cohen, & Rich, 2010).

The Evidence is there, Now What?
The evidence presented in this summary highlight the needs for and benefits of
implementing MAT programs in correctional facilities to treat OUD and improve the postrelease outcomes of individuals returning to their communities. However, one must consider
many factors that may influence the effectiveness of implementing proper treatment options
for incarcerated individuals with OUD. These factors include the cost of treatment during
incarceration and post-release; individuals’ treatment readiness; and their access to providers
waived and willing to provide buprenorphine or methadone for medication-assisted treatment
in their communities.
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Treatment Readiness and Social Support
Factors that shape patients’ readiness for change may influence treatment outcomes.
Readiness, self-efficacy, expectation about therapy outcomes, satisfaction with treatment can
have significant impacts on patients’ health outcomes during and after substance use treatment
(Flora and Stalikas, 2013). Flora and Stalikas (2013) defined treatment readiness as patients’
ability to realize their dependence on substance as a problem and take the initiative to
voluntarily enroll in treatment. Self-efficacy was measured as patients’ trust in themselves that
they can overcome addiction and attain successful health outcomes, such as retention in
treatment and abstinence (Flora & Stakilas, 2013 ). Flora and Stakilas (2013) found that
patients with previous treatment experience were more likely to recognize the seriousness of
their addiction and remain in treatment. In fact, treatment readiness proved to be a significant
predictor of remaining in treatment for at least 360 days (Flora & Stakilas, 2013).
Similar results were observed when assessing the impact of treatment readiness
among patients in an opioid maintenance therapy program (Joe, Flynn, Broome, & Simpson,
2007). A 110% increase in retention was observed for each unit increase in the treatment
readiness score reported by patients. Another study investigating factors that influence the
outcomes of buprenorphine for MAT found that social and internalized stigma were both
negatively associated with the ability to seek treatment and receptivity to treatment (Hewell,
Vasquez, & Rivkin, 2017). When asked about this, respondents reported that others see
addicts as “evil” (Hewell et al., 2017). As a result, individuals who are dependent on
substances refrain from seeking the treatment that they need (Hewell et al., 2017). This
highlights the need to change negative attitudes towards medication-assisted treatment on both
a systemic and individual level. Given this evidence, implementing medication-assisted
treatment programs in correctional facilities may increase individuals’ treatment readiness for
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post-release care. Future studies should assess the impact of implementing MAT programs
during incarceration on individuals’ self-internalized stigma towards substance use treatment
and changes in their perception regarding receiving treatment upon release.
A social environment and support can also play a role in the treatment outcomes.
Having recovery-oriented social support and not have a difficult living situation are both
positively associated with retention of 90 days or more (Rudd et al., 2016). Furthermore,
Rudd and colleagues reported that poor family relations, poly-drug use, and social
environment that encourage drug use (having friends who also use substances) are all
negatively associated with poor retention rates. On the other hand, patients who report high
levels of recovery-oriented social support are 2.6 times more likely to remain abstinent than
those who reported a lower level of support (Rudd et al., 2016). Similar trends were observed
among patients when measuring the impact of living situations. Patients who did not have
difficult living situations were 7.4 times more likely to remain abstinent compared to those
who had difficult living situations or lived with someone who uses alcohol or other illicit
drugs (Rudd et al., 2016). This highlights the importance of ensuring that individuals
transitioning from the incarceration to their communities should have access to proper
housing and recovery-oriented environments.

Cost of Treatment: Methadone vs. Buprenorphine
The cost of administering methadone or buprenorphine in corrections facilities to treat
OUD may differ. Health providers from the Magura et al., (2009) study preferred
administering methadone over buprenorphine for various reasons. On average, medical and
nursing staff reported devoted approximately 15 minutes per inmate per day to prepare for,
dispense, and monitor the ingestion of buprenorphine tablets during the study (Magura et al.,
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2009). In this study, buprenorphine/ naloxone (Suboxone Ⓡ )was distributed in the shape of a
sublingual tablet. Due to this, medical staff had to monitor the ingestion of buprenorphine
tablets to prevent medication diversion attempts (Magura et al., 2009). On the other hand, the
preparation and distribution of liquid methadone only took 1-3 minute per inmate. As a result,
more inmates can be served with methadone compared to buprenorphine using the same staff
resources and time. However, methadone requires daily administration whereas
buprenorphine can be administered on alternate dates without losing its efficacy (Amass,
Kamien, & Mikulich, 2000). Therefore, some may argue that this feature of buprenorphine
may balance the staff time needed for preparation and medication dispersion or even save staff
time to an extent compared to methadone (Magura et al., 2009).

Financial Resources
Due to the high cost associated with buprenorphine treatment, methadone is also more
integrated into the medical care and criminal justice system compared to buprenorphine
(Magura et al., 2009). Inmates tend to lose their Medicaid eligibility after release, which must
be reestablished (Gisev et al., 2015; Magura et al., 2009). Depending on the area where
individuals relocate upon release, access to buprenorphine treatment may be limited, unless
there are community health centers or small community providers waived and willing to
prescribe buprenorphine without the requiring Medicaid coverage. Zaller et al., 2013 found
that community resources were extremely limited to uninsured individuals. Specifically, 56%
of uninsured individuals did not have access to needed resources (Zaller et al., 2013).
Even upon reestablishment of Medicaid coverage, individuals may still struggle to
access buprenorphine treatment for MAT compared to methadone (Magura et al., 2009). For
instance, many community providers in cities, like New York City, do not accept Medicaid
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coverage for buprenorphine treatment due to the lower rates associated with buprenorphine
treatment (Magura et al., 2009; Zaller et al., 2013). In Zaller et al., 2013, many of the
participants who re-established their Medicaid coverage reported having limited options for
treatment. A possible solution to this issue would be the implementation of a generic form of
buprenorphine that is as effective as the original formula.

Access to Care Post-release
It is also important for states to increase the number of providers waived to prescribe
buprenorphine and accept Medicaid. Zaller et al., (2013) recommends the implementation of
statewide multidisciplinary efforts to support primary care providers to become waivered to
prescribe buprenorphine and collaborate with behavioral health providers to provide addiction
recovery treatment. We would recommend Project ECHO as an intervention to facilitate the
implementation of an interdisciplinary approach to treating opioid use disorders in former
inmates.
Project ECHO is Project Extension for Community Healthcare Outcomes (Project
ECHO®) was developed at the University of New Mexico to overcome the lack of access to
specialty care for Hepatitis C, but has been applied to a variety of medical conditions since its
initiation (Anderson et al., 2017; Arora et al., 2011; Komaromy et al., 2016). Project ECHO is
a telehealth model that utilizes video conferencing technology to connect a multidisciplinary
faculty of experts with clinicians who present cases and listen to short didactic lectures to gain
specialist expertise and knowledge to treat patients with complex health conditions (Arora et
al., 2011).
The Center for Rural Health at the University of North Dakota and the North Dakota
Department of Health Services (NDDHS) implemented Project ECHO to educate and support
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primary health providers to treat patients in rural areas with OUD and other substance use
conditions (Kusler, 2018). According to Dr. McClean, co-director for Project ECHO at UND,
“A major benefit of the TeleECHO clinic is access to a multidisciplinary group of experts and
peers in one virtual spot (Kusler, 2018).”
Numerous Federally Qualified Health Centers in the United States have adapted
Project ECHO (Anderson et al., 2017). A study investigating the impact of pain-focused
Project ECHO on providers’ knowledge and self-efficacy of pain treatment reported a
significant increase in providers’ knowledge and self- efficacy after participating in Project
ECHO (Anderson, Zlateva, & Moore, 2015). Project ECHO has also been shown to increase
providers’ competence, skills, and performance (Zhou, Crawford, Serhal, Kurdyak, &
Sockalingam, 2016).
Lastly, many community health centers employ Project ECHO as an intervention to
reduce the cost of healthcare services for those who live in rural areas with limited access to
specialty care (Zhou et al., 2016). Cost-effectiveness analyses evaluating the impact of an
HCV Project ECHO on patient outcomes found that that Project ECHO may increase qualityadjusted life expectancy by 3.8 years and save patients $1,352 on average (Zhou et al., 2016).
Another study showed that patients who live in rural areas saved an average of 187 travel
miles per person by seeing a primary care provider who participates in Project ECHO rather
than a specialist (Zhou et al., 2016).
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Implementing Statewide Interventions in Correctional Facilities
Given the health consequences of the lack of proper treatment for OUD in jails and
prisons, it is imperative for states to develop strategic initiatives to provide treatment for OUD
in correctional facilities and improve the post-release health outcomes of inmates. Rhode
Islands is one of the few states that have implemented such statewide intervention in their
corrections facilities. In 2015, the governor of Rhode Island incorporated corrections-based
recommendations in their overdose reduction plan by creating the Overdose Prevention and
Intervention Task Force (Montanaro et al., 2015). In an effort to improve treatment for OUD
in prisons and jails, the task force implemented MAT programs in their corrections facilities
for the treatment of OUD among incarcerated individuals.
The implementation of their statewide MAT programs in correctional facilities
resulted in a 61% reduction in overdose deaths, which accounted for an overall 12% reduction
in drug-overdose related deaths in the state (Green et al., 2018). This suggests that the
implementation of a comprehensive and multidisciplinary MAT treatment in jails and prisons,
with linkage to post-release treatment, is an effective strategy to address the opioid epidemic
not only in correctional settings but also during transitioning periods after release.

Conclusion
This summary provides limited support for the implementation of medication-assisted
treatment (MAT) programs in correctional facilities in the United States. There is strong
evidence of the ability for MAT programs to effectively treat OUD in incarcerated individuals
and improve their post-release health outcomes. Access to MAT during incarceration is
strongly associated with a higher likelihood of treatment continuation and lower risks for
illicit drug use, drug-overdose, HIV risk behaviors, among other outcomes. Given the
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overrepresentation of opioid use disorder (OUD) in prisons and jails and the lack of access to
care for those in need, this paper provides evidence regarding the importance of providing
proper care for OUD during incarceration. Using correctional settings as a venue to address
the opioid epidemic could benefit both incarcerated individuals and the communities to which
they return upon release. Rhode Island’s statewide implementation of MAT in correctional
facilities is good evidence that efforts to implement statewide strategies to address the opioid
epidemic in the incarcerated population can result in positive public health impacts (Green et
al., 2018). Most importantly, proper actions must be taken to ensure that individuals who
received opioid-substitution treatment during incarceration continue to have access to
recovery-oriented environments that can help them successfully reach positive health
outcomes.
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Appendix A
Table 1. Study Summary
Author(s),
date

Location
(State)

Setting

Design

Intervention

Comparator (s)

Outcomes

Followup

Methodological
Limitations

Impact on Study

BrinkleyRubinstein et
al., 2017

Rhode Island

Unified
prison and
jail system

Randomiz
ed
controlled
trial (RCT)

Methadone

Forced
withdrawal from
Methadone

1.
Treatment
retention
2.
Substance
use
3. Overdose
4. HIV risk
5. Reincarceratio
n

12
months

Setting
(unique state-wide
unified prison and jail
system)

Generalizability

Small sample size

Generalizability

Only included
individuals incarcerated
for 6 months or less and
differences in length of
sentence between the 2
groups

Selection bias

Loss to follow-up
Self-reported data

Selection bias
Response Bias

Loss to follow-up and
inability to conduct a
urine drug test on all
participants
Exclusive male
population prisoner
population in Baltimore

Selection bias

Kinlock,
2009

Baltimore

Prison

RCT

Methadone

1. Counseling
only
2. Counseling +
transfer

1.Treatment
retention
2. Urine
Drug Test
3. Drug use
days
4. Criminal
activity
5. Arrest
6.
Employmen
t
7. Serious
Adverse

12
months

Generalizability
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McKenzie,
2012

Magura, 2009

Gordon, 2017

Zaller, 2013

Springer,
2012

Rhode Island

New York

Baltimore

Rhode Island

Connecticut

Unified
prison and
jail system

Jail

Prison

Prison

Prison

RCT

RCT

RCT

RCT

RCT

Methadone

Buprenorphine

Buprenorphine

Buprenorphine

Buprenorphine

1. Referral for
Post-release
MMT with
financial
assistance
2. Referral to
post-release
MMT without
financial
assistance
Methadone

1. Post-release
buprenorphine
treatment in
OTP or
2. CHC

Post-release
initiation of
buprenorphine

1. Selfadministered
therapy (SAT)
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1. Time
until
treatment
re-entry
2. Overdose
Relapse

1.
Treatment
retention
2. Drug use
3. Reincarceratio
n
1.
Treatment
retention
2. Drug use

1.
Treatment
retention
2. Drug use
and
overdose
3. Reincarceratio
n
1.
Achieving
maximal
viral

6
months

Self-reported data

Social desirability
bias

Small sample size

Generalizability

Setting
(unique statewide
unified prison and jail
system)
Loss to follow-up

Generalizability

3
months

Loss to follow-up

Reduce Power

All male sample

Generalizability

1 month
3 month
6
months
12
months

Loss to follow-up

Selection bias,
Reduced Power

Self-reported data

Social desirability
bias

Predominantly African
American prison
population and fewer
women

Generalizability

Small sample size

Generalizability/
reduce power/
inability to conduct
12 month followup interviews
Reduce Power
Social desirability
bias

6
months

Loss to follow-up
Self-reported data
6
months

Selection bias

Small sample size

Generalizability/
Reduce Power

Non-randomization of
participants

Selection bias
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suppression
(MVS)

Rich, 2015

Rhode Island

Prison

RCT

Methadone

Black text- Experimental group received methadone for MAT
Purple Text- Experimental group received buprenorphine for MAT

Forced
withdrawal from
Methadone

1. Postrelease
treatment
entry
2.
Treatment
retention
3. Drug use
4. Overdose

1 month

Failure to control for
factors that may
influence retention
(homelessness, mental
illness, social support,
etc.).
Inability to control the
length of incarceration
Setting
(Single institution with a
predominantly white
population)

Reduced Power

Generalizability
Generalizability
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Appendix B
Table 2. Outcome Measures
Outcome
Studies with Positive Outcomes (P<0.05)
Treatment
retention

Drug Use

Overdose
HIV- risk
behavior
Other

Brinkley-Rubinstein et al., 2017
Kinlock et al., 2009
Magura, 2009
Gordon, 2017
Zaller, 2013
Rich, 2015
Brinkley-Rubinstein et al., 2017
Brinkley-Rubinstein et al., 2017
Kinlock et al., 2009
McKenzie, 2012
Zaller, 2013

No Effect/ No significant difference
(Outcomes, if other)

Magura, 2009
Gordon, 2017

Brinkley-Rubinstein et al., 2017
Springer, 2012

Rich, 2015
Rubenstein et al., 2017

McKenzie, 2012
(Time to treatment re-entry)

Rubenstein et al., 2017
(re-incarceration, visit to the emergency department, use of
prescription opioids, alcohol, cannabis, or other drugs)
Kinlock et al., 2009
(drug use days, criminal activity, arrests, employment)
Magura, 2009
(re-arrest)
Rich, 2015
(Visit to the emergency room, admission to hospital)

Zaller, 2013
(Re-incarceration)

Other

Black text- Methadone

Purple text- Buprenorphine
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